c1qb protein  (MedChemExpress)

Journal: Chinese Medical Journal

Article Title: FABP4 expression in neutrophils as a predictor of sepsis and SI-ARDS based on BALF transcriptome and peripheral blood validation

doi: 10.1097/CM9.0000000000003447

Figure Lengend Snippet: Downregulated FABP4 expression inhibits neutrophil apoptosis by activating the PI3K/AKT pathway. (A) WB analysis of expression levels of PDE4D, C1QB, RTN1, PRKDC, and FABP4 in neutrophils. (B) WB analysis of expression levels of caspase-3, caspase-8, caspase-9, BAX, BCL2, IL-10, IL-1β, IL-6, TNF-α, and MPO in neutrophils treated with or without BMS-309403. (C) WB analysis of expression levels of caspase-3, caspase-8, caspase-9, BAX, BCL2, IL-10, IL-1β, IL-6, TNF-α, and MPO in neutrophils treated with BMS-309403 and AZD5363. AKT: Protein kinase B; ARDS: Acute respiratory distress syndrome; AZD: AZD5363, an inhibitor of PI3K/AKT pathway; BAX: BCL2-associated X protein; BCL2: B-cell lymphoma 2; BM: BMS-309403, an inhibitor of FABP4; C1QB: Complement c1q B chain; FABP4: Fatty acid binding protein 4; IL: Interleukin; MPO: Myeloperoxidase; PDE4D: Primary antibodies against phosphodiesterase 4D; PI3K: Phosphatidylinositol 3 kinase; PRKDC: Protein kinase, DNA-activated, catalytic subunit; RTN1: Reticulon 1; TNF-α: Tumor necrosis factor-α; WB: Western blotting.

Article Snippet: The expression level of protein in neutrophils from peripheral blood was detected and the primary antibodies against phosphodiesterase 4D (PDE4D, 1:1000, # AWA47710 , Abiowell, Changsha, China), complement c1q B chain (C1QB, 1:1000, #16919-1-AP, Proteintech, Chicago, IL, USA), reticulon 1 (RTN1, 1:1000, # AWA49073 , Abiowell), protein kinase, DNA-activated, catalytic subunit (PRKDC, 1:5000, #ab32566, Abcam), FABP4 (1:10,000, #12802-1-AP, Proteintech), caspase-3 (1:1000, # AWA45562 , Abiowell), caspase-8 (1:1000, # AWA48554 , Abiowell), caspase-9 (1:1000, # AWA46480 , Abiowell), B-cell lymphoma 2 (BCL2, 1:1000, # AWA43352 , Abiowell), BCL2-associated X protein (BAX, 1:1000, # AWA47651 , Abiowell), interleukin-10 (IL-10, 1:1000, # AWA44364 , Abiowell), IL-1β (1:1000, # AWA46641 , Abiowell), IL-6 (1:1000, # AWA46788 , Abiowell), tumor necrosis factor-α (TNF-α, 1:1000, # AWA46292 , Abiowell), MPO (1:1000, # AWA42683 , Abiowell), and β-actin (1:5000, # AWA80002 , Abiowell) were used.

Techniques: Expressing, Binding Assay, Western Blot

Journal: Chinese Medical Journal

Article Title: FABP4 expression in neutrophils as a predictor of sepsis and SI-ARDS based on BALF transcriptome and peripheral blood validation

doi: 10.1097/CM9.0000000000003447

Figure Lengend Snippet: Downregulated FABP4 expression inhibits neutrophil apoptosis by activating the PI3K/AKT pathway. (A) WB analysis of expression levels of PDE4D, C1QB, RTN1, PRKDC, and FABP4 in neutrophils. (B) WB analysis of expression levels of caspase-3, caspase-8, caspase-9, BAX, BCL2, IL-10, IL-1β, IL-6, TNF-α, and MPO in neutrophils treated with or without BMS-309403. (C) WB analysis of expression levels of caspase-3, caspase-8, caspase-9, BAX, BCL2, IL-10, IL-1β, IL-6, TNF-α, and MPO in neutrophils treated with BMS-309403 and AZD5363. AKT: Protein kinase B; ARDS: Acute respiratory distress syndrome; AZD: AZD5363, an inhibitor of PI3K/AKT pathway; BAX: BCL2-associated X protein; BCL2: B-cell lymphoma 2; BM: BMS-309403, an inhibitor of FABP4; C1QB: Complement c1q B chain; FABP4: Fatty acid binding protein 4; IL: Interleukin; MPO: Myeloperoxidase; PDE4D: Primary antibodies against phosphodiesterase 4D; PI3K: Phosphatidylinositol 3 kinase; PRKDC: Protein kinase, DNA-activated, catalytic subunit; RTN1: Reticulon 1; TNF-α: Tumor necrosis factor-α; WB: Western blotting.

Article Snippet: The expression level of protein in neutrophils from peripheral blood was detected and the primary antibodies against phosphodiesterase 4D (PDE4D, 1:1000, # AWA47710 , Abiowell, Changsha, China), complement c1q B chain (C1QB, 1:1000, #16919-1-AP, Proteintech, Chicago, IL, USA), reticulon 1 (RTN1, 1:1000, # AWA49073 , Abiowell), protein kinase, DNA-activated, catalytic subunit (PRKDC, 1:5000, #ab32566, Abcam), FABP4 (1:10,000, #12802-1-AP, Proteintech), caspase-3 (1:1000, # AWA45562 , Abiowell), caspase-8 (1:1000, # AWA48554 , Abiowell), caspase-9 (1:1000, # AWA46480 , Abiowell), B-cell lymphoma 2 (BCL2, 1:1000, # AWA43352 , Abiowell), BCL2-associated X protein (BAX, 1:1000, # AWA47651 , Abiowell), interleukin-10 (IL-10, 1:1000, # AWA44364 , Abiowell), IL-1β (1:1000, # AWA46641 , Abiowell), IL-6 (1:1000, # AWA46788 , Abiowell), tumor necrosis factor-α (TNF-α, 1:1000, # AWA46292 , Abiowell), MPO (1:1000, # AWA42683 , Abiowell), and β-actin (1:5000, # AWA80002 , Abiowell) were used.

Techniques: Expressing, Binding Assay, Western Blot